$CTIC Headlines Insider filings one way to track tricky

New Post Public Reply Private Reply Replies (0) Message Board

Apr 12, 2014 at 10:20 AM

$CTIC Headlines

Insider filings one way to track tricky micro-cap biotechs 12:14 p.m. Oct. 24, 2012 - blogs.marketwatch.com
Friday’s biggest gaining and declining stocks 4:27 p.m. Oct. 5, 2012 - Greg Morcroft
Cell Therapeutics down 21% in premarket 7:15 a.m. Oct. 5, 2012 - Steve Gelsi
Tuesday’s biggest gaining and declining stocks 4:53 p.m. Oct. 2, 2012 - MarketWatch
Cell Therapeutics up 21% in premarket 8:38 a.m. Oct. 2, 2012 - Steve Gelsi
CTIC gets orphan drug status for brain cancer drug 7:37 a.m. Oct. 2, 2012 - MarketWatch.com
Cell Therapeutics: progress with lymphoma Drug 6:59 a.m. Sept. 24, 2012 - MarketWatch.com
Tuesday’s top gaining and declining stocks 4:57 p.m. Sept. 11, 2012 - MarketWatch
Cell Therapeutics soars 24% on EU drug launch 10:12 a.m. Sept. 11, 2012 - Val Brickates Kennedy
Tuesday’s biggest gaining and declining stocks 5:01 p.m. Sept. 4, 2012 - Greg Morcroft
Updates, advisories and surprises 5:01 p.m. July 31, 2012 - MarketWatch
Cell Therapeutics announces stock placement 11:45 a.m. July 31, 2012 - Val Brickates Kennedy
Friday’s biggest gaining and declining stocks 5:21 p.m. Feb. 17, 2012 - Kate Gibson
Monday’s biggest gaining and declining stocks 5:49 p.m. Jan. 30, 2012 - Kate Gibson
Cell Therapeutics pulls application; shares slump 2:25 p.m. Jan. 30, 2012 - MarketWatch.com
Stocks to watch Monday: Blue Coat, Cooper 5:35 p.m. Dec. 9, 2011 - William Spain
Friday’s biggest gaining & declining stocks 5:35 p.m. Dec. 9, 2011 - Kate Gibson
Thursday’s biggest gaining & declining stocks 4:59 p.m. June 30, 2011 - Kate Gibson
Cell Therapeutics tumbles over offerings 9:09 a.m. June 30, 2011 - MarketWatch.com

Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 11.4% in Session - Tale of the Tape 9:21 a.m. April 10, 2014 - Zacks.com
Insider Trading Alert - CTIC, KR And IBKR Traded By Insiders 10:45 a.m. March 31, 2014 - TheStreet.com
Zacks Rank #1 Additions for Friday - Tale of the Tape 9:30 a.m. March 28, 2014 - Zacks.com
First Week Of CTIC May 17th Options Trading 12:54 p.m. March 26, 2014 - TheStreet.com
Cell Therapeutics: 5 Different Insiders Have Sold Shares This Month 10:39 a.m. March 24, 2014 - Seeking Alpha
Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc. ... 10:12 a.m. March 24, 2014 - GuruFocus.com
Geron: FDA Suspends Key Myelofibrosis Drug Due to Liver Safety Concerns 9:57 a.m. March 12, 2014 - TheStreet.com
Insider Trading Alert - CTIC, TCBI And FCS Traded By Insiders 1:16 p.m. March 10, 2014 - TheStreet.com
Is It Too Late to Buy the Rally in Small Caps? 12:00 a.m. March 7, 2014 - InvestorPlace.com
Cell Therapeutics' CEO Discusses Q4 2013 Results - Earnings Call Transcript 9:21 p.m. March 4, 2014 - Seeking Alpha
10-K: CELL THERAPEUTICS INC 5:32 p.m. March 4, 2014 - Edgar Online - (EDG = 10Q, 10K)
Cell Therapeutics Q4 revenue soars due to Baxter license payment 4:49 p.m. March 4, 2014 - Seeking Alpha
Cell Therapeutics' Pixuvri gets final NICE recommendation 9:47 a.m. Feb. 27, 2014 - Seeking Alpha
Interesting CTIC Put And Call Options For April 19th 11:01 a.m. Feb. 26, 2014 - TheStreet.com
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule 7:33 a.m. Feb. 26, 2014 - TheStreet.com
TetraLogic Pharmaceuticsls And The Chatter About A Cure For Cancer 5:18 p.m. Jan. 31, 2014 - Seeking Alpha
Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown 6:00 a.m. Jan. 31, 2014 - TheStreet.com
Is The Healthcare Sector Pulling Back Or Crashing? 5:40 a.m. Jan. 28, 2014 - Seeking Alpha
First Week Of CTIC January 2016 Options Trading 1:18 p.m. Jan. 22, 2014 - TheStreet.com
Cell Therapeutics (CTIC) Highlighted As Today's Perilous Reversal Stock 9:46 a.m. Jan. 22, 2014 - TheStreet.com

Insider Trading Research -- Alerts for Ariad Pharmaceuticals, Cell Therapeutics, Staples, Sirius XM, Facebook, and Bank of America 8:55 a.m. March 25, 2014 - PR Newswire - PRF
Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics 8:00 a.m. March 18, 2014 - PR Newswire - PRF
Investor-Edge.com Most Active Equities Watch List: Cell Therapeutics, Yandex, Himax Technologies, and CytRx 8:54 a.m. March 14, 2014 - PR Newswire - PRF
Cell Therapeutics to Present at the 26th Annual ROTH Conference 2:30 a.m. March 5, 2014 - PR Newswire - PRF
Cell Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results 5:00 p.m. March 4, 2014 - PR Newswire - PRF
CTI Opens Enrollment for PERSIST-2 Phase 3 Trial of Pacritinib for Patients with Myelofibrosis Who Have Low Platelet Counts 2:30 a.m. March 3, 2014 - PR Newswire - PRF
NICE Publishes Final Guidance on PIXUVRI® (pixantrone) 2:30 a.m. Feb. 27, 2014 - PR Newswire - PRF
Cell Therapeutics to Report Fourth Quarter and Full Year 2013 Financial Results on March 4, 2014 2:30 a.m. Feb. 25, 2014 - PR Newswire - PRF
Hercules Offshore Losses Decrease from $121 million to $27 million 10:17 a.m. Feb. 24, 2014 - ACCESSWIRE
Glu Mobile and Siri XM Stock Volume Soars on Fourth-Quarter Results: Glu Mobile Inc.'s (NASDAQ: GLUU), Sirius XM Holdings Inc. (NASDAQ: SIRI), Zynga Inc. (NASDAQ:ZNGA, Cell Therapeutics Inc. (NASDAQ:CTIC) 11:12 a.m. Feb. 11, 2014 - ACCESSWIRE
Cell Therapeutics Appoints Karen Ignagni to Board of Directors 2:30 a.m. Feb. 3, 2014 - PR Newswire - PRF
CTI Announces United Kingdom National Cancer Research Institute AML Cooperative Group Phase 2 Trial Evaluating Pacritinib for Patients with Relapsed FLT3 Positive Acute Myeloid Leukemia 2:30 a.m. Jan. 30, 2014 - PR Newswire - PRF
Cell Therapeutics Announces GOG Completes Patient Enrollment in GOG-0212 Phase 3 Clinical Trial of Paclitaxel Poliglumex (Opaxio™) as Maintenance Therapy in Ovarian Cancer 2:30 a.m. Jan. 28, 2014 - PR Newswire - PRF
Most Active Stocks Range from Online Game Maker to Biopharmaceuticals: Zynga Inc. (NASDAQ:ZNGA), Dynavax Technologies Corp. (NASDAQ: DVAX), Cell Therapeutics Inc. (NASDAQ:CTIC) 8:23 a.m. Jan. 20, 2014 - ACCESSWIRE
Morning Buzzers: Cell Therapeutics Inc, Stratasys, Galena Biopharma, Cliffs Natural Resources 11:52 a.m. Jan. 14, 2014 - ACCESSWIRE
Cell Therapeutics Announces 2014 Outlook and Recent Drug Portfolio Progress 2:30 a.m. Jan. 14, 2014 - PR Newswire - PRF
Cell Therapeutics Reaches Agreement to Reacquire Rights to Two Anti-Cancer Compounds 2:30 a.m. Jan. 13, 2014 - PR Newswire - PRF
Study Updates, Notices, Quarterly Reports, and Revenue Guidance Updates - Research Report on NPS Pharmaceuticals, Oramed, PAREXEL, PhotoMedex, and Cell Therapeutics 9:00 a.m. Jan. 7, 2014 - PR Newswire
PIXUVRI® (pixantrone) Receives Positive Final Appraisal Determination from NICE 2:30 a.m. Jan. 6, 2014 - PR Newswire
Biotech Industry Stock Update: Cell Therapeutics, Sarepta Therapeutics, ACADIA Pharma, and Medivation 9:00 a.m. Jan. 2, 2014 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

First Industrial Declares Regular Dividend Amid Growth Insights

Dividend Declaration Reflects Confidence First Industrial Realty Trust, folks, just put another office stamp on their ongoing reliability quest—and I'm talking dividends. They're shelling out a tidy $0.50 per share for Q4 2026, with stockholders due to see the cash on January 19, 2027. That's like clockwork precision, showing a steadiness in what some call the unruly...

Trimble's Q3 2026: Guidance Update and Record ARR

Trimble Smashes Through Q3 Expectations Trimble Inc. (NASDAQ:TRMB) tossed a bit of a curveball by posting Q3 2026 results that sailed past analyst forecasts. We’re talking revenue swelling to $966.8 million, a decent 7% bump from the previous year. Now, for a company riding its 'Connect & Scale' strategy, this serves as a validation of its aggressive scaling ambitions....

Fractal Sees Explosive Q2 Gain: Revenue Hits $100M

Fractal’s Revenue Moment: Climbing New Peaks Fractal Analytics just knocked it out of the park, folks. Imagine this—an AI company pulling in $100 million for the first quarter, getting a 20% jump in revenue year on year. That's right, these numbers aren't just fancy figures; they're staggering proof that Fractal's hitting its AI stride. The healthcare and life...

Zuellig Pharma Expands Clinical Capabilities in China

Zuellig Pharma's Strategic Leap in Hangzhou You know, in the ever-evolving world of biotech and pharmaceuticals, setting up shop in the right locale can mean the difference between breakthroughs and breakdowns. So Zuellig Pharma—a major player, but not exactly a household ticker—made a smart move acquiring a clinical facility in Hangzhou. This is no minor shuffle;...

Natixis' $100M Student Challenge Mixes Real Stakes

Opportunity Knocks for Budding Portfolio Managers Picture this: You're a student, neck-deep in textbooks and theories, and then bam! You're handed the keys to manage a $100 million portfolio. That's the real-deal opportunity Natixis Investment Managers is dangling with its seventh Students Challenge. Diving Into the Nuts and Bolts Listen up, kids. Applications are open...

VAB's Pharma Ad Guide: Emerging Trends and Insights

Pharma's not just popping pills anymore; it's a whole show on multiscreen TV. The Video Advertising Bureau (VAB) just dropped a bombshell of a guide called The Pharmacy, diving into the state of pharmaceutical direct-to-consumer (DTC) advertising. Over the past year and a half, VAB's been grilling agencies, media folks, and anyone else with skin in the game to sketch the...

Coretek Joins CRN's Elite AI Innovators of 2026

Coretek's Leap to AI Innovator Status Here we are, folks. Another announcement hits the wires that showcases a company's ascent amid the swelling AI tide. Coretek, hailing from Farmington Hills, managed to snag a spot on CRN's inaugural 2026 AI Innovators list. No small potatoes, if you ask me, considering the competition on this playing field. Why the fuss? It's about...

Allego Dominates 2026 Gartner Magic Quadrant: Why It Matters

Allego Secures Top Spot Yet Again I've seen companies rise and fall on the whims of industry recognition, and let me tell ya, Allego's riding high on the right wave. For the second year running, this outfit's been named a Leader in the 2026 Gartner Magic Quadrant for Revenue Enablement Platforms. Recognized for its Completeness of Vision—yeah, that's no small feat...

KOVE's Bold Lineup Expansion at EICMA 2026

By Logan Wright Updated Nov 3, 2026 Category News Views 112

What's Roaring: The Latest from KOVE Anybody who’s been following motorcycle trends knows that EICMA 2026 was destined to be a spectacle, and KOVE didn’t disappoint. They rolled out a fleet of five new models, including the 125 RALLY, 350 RALLY, 650RR, and two head-turners on the electric front: the BONIC and the E-500RR. Each model brings something fresh to the...

Askey & Icom Team Up: Trading Airwaves for Partnerships

Old-School Radios Meet Cutting-Edge 5G When I hear about a company linking their old-school tech with shiny new 5G jazz, skepticism kicks in fast. But then comes this announcement: Askey and Icom America are joining forces to bring 5G networks with integrated two-way radio systems to various sectors—like a classic combo meal with a tech twist. The key audience? Utility...